NCT01336465View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL

Enrollment

124

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

June 30, 2013

Conditions

Ulcerative Colitis

Interventions

DRUG

placebo

Repeating subcutaneous injection

DRUG

rhuMAb Beta7

Repeating subcutaneous injection

Trial Locations (51)

1023

Auckland

1073

Budapest

1136

Budapest

1640

Auckland

2605

Garran

2820

Bonheiden

3000

Leuven

3050

Parkville

3065

Fitzroy

3168

Clayton

3181

Melbourne

3200

Gyöngyös

4000

Liège

8011

Christchurch

9000

Ghent

9024

Győr

9054

Dunedin

9200

Mosonmagyaróvár

11021

Great Neck

13353

Berlin

20815

Chevy Chase

24105

Kiel

30308

Atlanta

30625

Hanover

31096

Haifa

32423

Minden

32610

Gainesville

45219

Cincinnati

52621

Ramat Gan

55905

Rochester

64239

Tel Aviv

84105

Beersheba

89081

Ulm

91031

Jerusalem

92103

San Diego

48109-0682

Ann Arbor

T6G 2X8

Edmonton

V6Z 1Y6

Edmonton

N6A 5W9

London

L4L 4Y7

Woodbridge

500 12

Hradec Králové

547 01

Náchod

708 52

Ostrava - Poruba

762 75

Zlín

0620

Takapuna

08003

Barcelona

08036

Barcelona

HA1 3UJ

Harrow

N6A 4L6

London

SW10 9NH

London

NE1 4LP

Newcastle upon Tyne

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT01336465 - Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter